

References

I-152

1. BioMarin Nederland BV. A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects. NLM Identifier: NCT01803412.
2. Food and Drug Administration (FDA) Briefing Document: Peripheral and Central Nervous System Drugs Advisory Committee Meeting. January 22, 2016.
3. Sarepta Therapeutics. An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy. NLM Identifier: NCT02420379.
4. Sarepta Therapeutics. Confirmatory Study of Eteplirsen in DMD Patients (PROMOVI). NLM Identifier: NCT02255552.
5. Mendell J, Goemans N, Lowes L, et al. Longitudinal Effect of Eteplirsen Versus Historical Control on Ambulation in Duchenne Muscular Dystrophy. *Ann Neurol*. 2019;79:257-271.
6. Exondys 51 (eteplirsen), injection, for intravenous use [package insert]. Sarepta. Cambridge, MA. Revised 07/2020
7. Agboola F., Lin G.A., Fluetsch, N.Alton, S.M, et. al The effectiveness and value of deflazacort and exon-skipping therapies for the management of duchenne muscular dystrophy: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. *Journal of Managed Care & Specialty Pharmacy*, 2020. 26(4):361-366.
8. Kinane TB, Mayer OH, Duda PW, et. al. Long-term pulmonary function in duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. *J Neuromuscul Dis*. 2018;5(1):47-58.
9. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Eteplirsen.
10. Micromedex DrugDex Compendium®. 2020. Eteplirsen (Exondys 51).